[go: up one dir, main page]

MA40403A - Méthodes de traitement de paramyxovirus - Google Patents

Méthodes de traitement de paramyxovirus

Info

Publication number
MA40403A
MA40403A MA040403A MA40403A MA40403A MA 40403 A MA40403 A MA 40403A MA 040403 A MA040403 A MA 040403A MA 40403 A MA40403 A MA 40403A MA 40403 A MA40403 A MA 40403A
Authority
MA
Morocco
Prior art keywords
treating
methods
paramyxoviruses
methylpropanoate
cytidine
Prior art date
Application number
MA040403A
Other languages
English (en)
Inventor
Lawrence M Blatt
Sushmita Mukherjee Chanda
John Fry
Qingling Zhang
Original Assignee
Alios Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alios Biopharma Inc filed Critical Alios Biopharma Inc
Publication of MA40403A publication Critical patent/MA40403A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne des procédés pour l'amélioration et/ou le traitement d'une infection à paramyxovirus, ou l'inhibition de la réplication d'un paramyxovirus, par l'utilisation de 3',5'-(2-méthylpropanoate-4'-c-(chlorométhyl)-2'-désoxy-2'-fluoro-cytidine (composé a)), le composé (a) ou son sel pharmaceutiquement acceptable pouvant fournir 4'-c-chlorométhyl-2'-désoxy-2'-fluoro-5'- (tétrahydrogène triphosphate)-cytidine ou son sel pharmaceutiquement acceptable (composé (b)).
MA040403A 2014-07-22 2015-07-20 Méthodes de traitement de paramyxovirus MA40403A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462027719P 2014-07-22 2014-07-22

Publications (1)

Publication Number Publication Date
MA40403A true MA40403A (fr) 2017-05-31

Family

ID=55163588

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040403A MA40403A (fr) 2014-07-22 2015-07-20 Méthodes de traitement de paramyxovirus

Country Status (13)

Country Link
US (1) US20160022724A1 (fr)
EP (1) EP3171878A4 (fr)
JP (1) JP2017525681A (fr)
KR (1) KR20170031231A (fr)
AU (1) AU2015294343A1 (fr)
BR (1) BR112017001162A2 (fr)
CA (1) CA2955604A1 (fr)
CL (1) CL2017000156A1 (fr)
MA (1) MA40403A (fr)
MX (1) MX2017000983A (fr)
RU (1) RU2017105470A (fr)
TW (1) TW201609104A (fr)
WO (1) WO2016014398A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012358803C1 (en) 2011-12-22 2019-12-19 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA2860234A1 (fr) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Analogues de nucleotide phosphorothioate substitue
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AU2013361193B2 (en) 2012-12-21 2018-05-24 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
JP6284547B2 (ja) 2012-12-21 2018-02-28 アリオス バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
CA2908313A1 (fr) 2013-04-05 2014-10-09 Alios Biopharma, Inc. Traitement contre une infection par le virus de l'hepatite c utilisant une combinaison de composes
AU2014302715B2 (en) 2013-06-26 2018-12-06 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9815864B2 (en) 2013-06-26 2017-11-14 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP3055319A4 (fr) 2013-10-11 2018-01-10 Alios Biopharma, Inc. Nucléosides substitués, nucléotides substitués et analogues de ceux-ci
CN106573011A (zh) 2014-06-24 2017-04-19 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸和其类似物
US9603863B2 (en) 2014-06-24 2017-03-28 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2016022464A1 (fr) * 2014-08-05 2016-02-11 Alios Biopharma, Inc. Polythérapie pour traiter un paramyxovirus
WO2016069489A1 (fr) 2014-10-28 2016-05-06 Alios Biopharma, Inc. Procédés de préparation d'analogues de nucléosides substitués
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MX383931B (es) 2015-03-11 2025-03-14 Janssen Biopharma Inc Compuestos de aza-piridona y usos de estos.
US20180117042A1 (en) * 2016-10-27 2018-05-03 Alios Biopharma, Inc. Methods for treating respiratory syncytial virus infection
WO2018222774A1 (fr) * 2017-05-30 2018-12-06 Alios Biopharma, Inc. Méthodes de traitement des pneumovirus
CN113462656B (zh) * 2021-03-24 2022-09-30 兰州生物制品研究所有限责任公司 一种人三型副流感病毒冷适应温度敏感株及其应用
IL315480A (en) 2022-03-15 2024-11-01 Rome Therapeutics Inc Compounds and methods for treating disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679901B2 (en) * 1991-08-26 1997-07-17 Scripps Research Institute, The Peptides for inducing cytotoxic T-lymphocyte responses to hepatitis B virus
JPH0859508A (ja) * 1994-08-16 1996-03-05 Teijin Ltd サイトメガロウイルス網膜炎予防または治療剤
DK2585467T3 (en) * 2010-06-24 2016-06-13 Gilead Sciences Inc PYRAZOLO [1,5-A] PYRIMIDINES AND TRIAZINES AS ANTIVIRAL AGENTS
AU2012358803C1 (en) * 2011-12-22 2019-12-19 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG10201804571TA (en) * 2012-03-21 2018-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof

Also Published As

Publication number Publication date
US20160022724A1 (en) 2016-01-28
BR112017001162A2 (pt) 2017-11-14
WO2016014398A1 (fr) 2016-01-28
CL2017000156A1 (es) 2017-11-03
TW201609104A (zh) 2016-03-16
MX2017000983A (es) 2017-09-01
EP3171878A1 (fr) 2017-05-31
RU2017105470A3 (fr) 2019-02-28
RU2017105470A (ru) 2018-08-22
JP2017525681A (ja) 2017-09-07
EP3171878A4 (fr) 2018-03-14
KR20170031231A (ko) 2017-03-20
CA2955604A1 (fr) 2016-01-28
AU2015294343A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
MA40403A (fr) Méthodes de traitement de paramyxovirus
SG10201901010PA (en) Combination therapy for treating a paramyxovirus
IL276883A (en) "Compositions, devices, systems, kits and methods for treating skin conditions"
PL3672954T3 (pl) Związki, ich sole i ich zastosowanie w leczeniu chorób
WO2016044556A3 (fr) Inhibiteurs d'arginine méthyltransférase et leurs utilisations
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
PH12015501588B1 (en) Compounds and methods for treating bacterial infections
EP3212658A4 (fr) Analogues de 2',2'-dihalo-nucléosides utilisables en vue du traitement d'infections par des virus de la famille des flaviviridae et du cancer
IL283096A (en) Medical tool positioning devices, systems, and methods of use and manufacture
MY202127A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
SG11201702766YA (en) Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv)
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX2017013047A (es) Tratamiento de dolor.
MX2020005707A (es) Profarmacos de creatina, composiciones y metodos de uso de estos.
EP3253312A4 (fr) Plaques osseuses, systèmes et procédés d'utilisation
ZA201802399B (en) Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
EP3269369A4 (fr) Agent de traitement d'une infection respiratoire
MX2019005504A (es) Potenciadores de bmp.
MY186775A (en) Antibacterial compositions and methods
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.
HK1231714A1 (en) Skin-referencing surgical guides
HK1263210A1 (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
HK1231715A1 (en) Spring-fit surgical guides